Table 2 Demographic and clinical characteristics of the patients from whom CSF samples were studied. Case (AD); control (C); p (Student’s t-test)
Case(n = 15) | C(n = 15) | P | |
|---|---|---|---|
Male | 4 (26.7%) | 5 (33.3%) | 0.7 |
Years | 73.5 ± 12,1 | 70.5 ± 7,1 | 0.6 |
Age schooling | 11.3 ± 5,0 | 11.3 ± 2,2 | 0.2 |
MMSE | 19,1 ± 6,0 | 28,1 ± 1,8 | 0 |
Family history | |||
Presenilin AD | 2(13.3%) | 0(0%) | 0.14 |
EA > 65 years | 3(20.0%) | 5(33.3%) | 0.4 |
Pathological history | |||
Hypertension | 6(40%) | 8(53%) | 0.46 |
Diabetes | 3(20.0%) | 2(13.3%) | 0.6 |
Hypercolesterolemia | 2(13.3%) | 7(46.7%) | 0.04 |
Depression | 2(13.3%) | 7(46.7%) | 0.04 |
CSF AD Biomarkers | pg/ml | pg/ml | |
Amyloid β | 386,128 | 856 ± 204 | 0 |
Total Tau | 615 ± 270 | 281 ± 103 | 0.01 |
PhosphoTau | 85 ± 28 | 55 ± 18 | 0 |